PharmaShots | Incisive News in 3 Shots

Subscribe Now

Metastatic Esophageal Cancer

Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS ≥10)

Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophag...

July 31, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us